Christian Hermann Ottensmeier

List of Publications by Year
in descending order

234 papers	38,604 citations	16451 64 h-index	2895 190 g-index
249 all docs	249 docs citations	249 times ranked	44238 citing authors

#	Article	IF	Citations
1	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	27.0	13,065
2	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	27.0	6,976
3	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	27.0	1,976
4	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	27.8	1,287
5	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	28.9	968
6	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	4.4	676
7	Neoantigen-directed immune escape in lung cancer evolution. Nature, 2019, 567, 479-485.	27.8	639
8	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
9	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, The, 2008, 372, 117-126.	13.7	620
10	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell, 2018, 33, 649-663.e4.	16.8	448
11	Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell, 2020, 183, 1340-1353.e16.	28.9	431
12	Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nature Immunology, 2017, 18, 940-950.	14.5	407
13	DNA vaccines: precision tools for activating effective immunity against cancer. Nature Reviews Cancer, 2008, 8, 108-120.	28.4	388
14	Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. British Journal of Cancer, 2014, 110, 489-500.	6.4	326
15	Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. Science Translational Medicine, 2014, 6, 254ra128.	12.4	325
16	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	14.3	323
17	Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet, The, 2008, 371, 1685-1694.	13.7	250
18	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood, 2002, 99, 2562-2568.	1.4	237

#	Article	IF	Citations
19	NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. Cancer Research, 2020, 80, 1846-1860.	0.9	189
20	Response definition criteria for ELISPOT assays revisited. Cancer Immunology, Immunotherapy, 2010, 59, 1489-1501.	4.2	188
21	Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2–reactive CD8⁺ T cells. Science Immunology, 2021, 6, .	11.9	185
22	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunology, Immunotherapy, 2016, 65, 161-169.	4.2	175
23	DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. Human Gene Therapy, 2009, 20, 1269-1278.	2.7	172
24	Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. Journal of Experimental Medicine, 2019, 216, 2128-2149.	8.5	160
25	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncology, The, 2016, 17, 212-223.	10.7	158
26	A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 2192-2204.	7.0	147
27	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
28	The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunology, Immunotherapy, 2008, 57, 289-302.	4.2	138
29	Expression and Function of Î²1 and Î±vÎ²3 Integrins in Ovarian Cancer. Gynecologic Oncology, 1995, 58, 216-225.	1.4	135
30	The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. European Journal of Surgical Oncology, 2014, 40, 1313-1320.	1.0	135
31	Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. Journal of the National Cancer Institute, 2018, 110, 109-120.	6.3	134
32	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. Blood, 1998, 91, 4292-4299.	1.4	133
33	Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunological Reviews, 1998, 162, 247-259.	6.0	132
34	T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity, 2012, 37, 1-2.	14.3	131
35	Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1530-1540.	10.7	130
36	Immunoglobulin Heavy Chain Locus Events and Expression of Activation-Induced Cytidine Deaminase in Epithelial Breast Cancer Cell Lines. Cancer Research, 2006, 66, 3996-4000.	0.9	119

#	Article	IF	Citations
37	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 895-904.	10.7	111
38	DNA vaccines to attack cancer. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14646-14652.	7.1	109
39	A randomised, phase II study of intetumumab, an anti-Î±v-integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer, 2011, 105, 346-352.	6.4	108
40	Autophagy inhibition-mediated epithelialâ€"mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death and Disease, 2019, 10, 591.	6.3	107
41	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood, 2002, 100, 1505-1507.	1.4	105
42	Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. Journal of the National Cancer Institute, 2014, 106, .	6.3	105
43	Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. Journal of Clinical Oncology, 2016, 34, 4132-4141.	1.6	105
44	Paracrine signalling during ZEB1-mediated epithelialâ€"mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death and Differentiation, 2019, 26, 943-957.	11.2	104
45	Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. ELife, 2018, 7, .	6.0	99
46	M1^{hot}tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. , 2020, 8, e000778.		99
47	The occurrence and significance of V gene mutations in B cellâ€"Derived human malignancy. Advances in Cancer Research, 2001, 83, 81-116.	5.0	95
48	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology, 2016, 11, 1511-1521.	1.1	95
49	Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). Journal of Clinical Oncology, 2017, 35, 1506-1514.	1.6	92
50	Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 651-662.	4.2	91
51	Recurrent group A *Streptococcus* tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T$_{FH}$ cells. Science Translational Medicine, 2019, 11, .	12.4	90
52	DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. Cancer Immunology, Immunotherapy, 2012, 61, 2161-2170.	4.2	89
53	Uveal Melanoma UK National Guidelines. European Journal of Cancer, 2015, 51, 2404-2412.	2.8	89
54	Harmonization of Immune Biomarker Assays for Clinical Studies. Science Translational Medicine, 2011, 3, 108ps44.	12.4	87

#	ARTICLE	IF	CITATIONS
55	Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget, 2016, 7, 56781-56797.	1.8	86
56	Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis. Aging, 2016, 9, 114-132.	3.1	86
57	CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors.. Journal of Clinical Oncology, 1995, 13, 1912-1921.	1.6	84
58	Upregulated Glucose Metabolism Correlates Inversely with CD8+ T-cell Infiltration and Survival in Squamous Cell Carcinoma. Cancer Research, 2016, 76, 4136-4148.	0.9	83
59	Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. Clinical Cancer Research, 2015, 21, 1321-1328.	7.0	81
60	Treatment of advanced chronic lymphocytic leukemia by fludarabine. Annals of Hematology, 1991, 63, 1-4.	1.8	80
61	DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunological Reviews, 2004, 199, 156-180.	6.0	78
62	Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. ELife, 2020, 9, .	6.0	76
63	Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. OncoImmunology, 2016, 5, e1143997.	4.6	74
64	FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. British Journal of Cancer, 2013, 109, 387-394.	6.4	72
65	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Annals of Oncology, 2014, 25, 968-974.	1.2	68
66	Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 5248-5254.	1.6	65
67	Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Journal of Surgical Oncology, 2018, 117, 1170-1178.	1.7	65
68	DNA vaccines against cancer come of age. Current Opinion in Immunology, 2010, 22, 264-270.	5.5	63
69	Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. Nature Immunology, 2021, 22, 1052-1063.	14.5	61
70	Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody. PLoS ONE, 2015, 10, e0118096.	2.5	58
71	Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. British Journal of Haematology, 2003, 120, 217-222.	2.5	56
72	Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood, 2009, 113, 4677-4680.	1.4	56

#	ARTICLE	IF	CITATIONS
73	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health and Quality of Life Outcomes, 2012, 10, 66.	2.4	55
74	Melanoma sentinel node biopsy and prediction models for relapse and overall survival. British Journal of Cancer, 2010, 103, 1229-1236.	6.4	54
75	Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1451-1453.	5.6	54
76	Vinflunine â€" an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. British Journal of Cancer, 2006, 94, 1383-1388.	6.4	53
77	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunology, Immunotherapy, 2010, 59, 863-873.	4.2	53
78	Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Molecular Immunology, 2008, 45, 1567-1572.	2.2	52
79	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
80	Ipilimumab in the real world. Melanoma Research, 2015, 25, 432-442.	1.2	50
81	Staging and treatment of oropharyngeal cancer in the human papillomavirus era. Head and Neck, 2015, 37, 1002-1013.	2.0	49
82	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. British Journal of Cancer, 2011, 105, 353-359.	6.4	48
83	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Annals of Oncology, 2013, 24, 2875-2880.	1.2	48
84	HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. Cells, 2020, 9, 2103.	4.1	48
85	Harmonization of the intracellular cytokine staining assay. Cancer Immunology, Immunotherapy, 2012, 61, 967-978.	4.2	47
86	Infliximab for IPILIMUMAB-Related Colitisâ€"Letter. Clinical Cancer Research, 2015, 21, 5642-5643.	7.0	47
87	Evaluating the effect of immune cells on the outcome of patients with mesothelioma. British Journal of Cancer, 2017, 117, 1341-1348.	6.4	47
88	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 2018, 29, 1843-1852.	1.2	47
89	<scp>NYâ€ESO</scp>â€1 specific antibody and cellular responses in melanoma patients primed with <scp>NYâ€ESO</scp>â€1 protein in <scp>ISCOMATRIX</scp> and boosted with recombinant <scp>NYâ€ESO</scp>â€1 fowlpox virus. International Journal of Cancer, 2015, 136, E590-601.	5.1	46
90	An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing. Scientific Reports, 2019, 9, 9580.	3.3	46

#	Article	IF	Citations
91	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). European Journal of Cancer, 2013, 49, 2815-2822.	2.8	45
92	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	3.8	45
93	Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. OncoImmunology, 2019, 8, e1593810.	4.6	44
94	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. International Journal of Cancer, 2020, 146, 2305-2314.	5.1	44
95	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials, 2018, 19, 233.	1.6	41
96	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	3.8	41
97	HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma. British Journal of Cancer, 2019, 120, 356-367.	6.4	41
98	Immunosuppression for ipilimumab-related toxicity can cause *pneumocystis* pneumonia but spare antitumor immune control. OncoImmunology, 2015, 4, e1040218.	4.6	39
99	Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. International Immunology, 2010, 22, 875-887.	4.0	38
100	Recent advances in the molecular landscape of lung neuroendocrine tumors. Expert Review of Molecular Diagnostics, 2019, 19, 281-297.	3.1	38
101	Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 136-141.	2.2	37
102	A plant-expressed conjugate vaccine breaks CD4$^+$ tolerance and induces potent immunity against metastatic Her2$^+$ breast cancer. OncoImmunology, 2016, 5, e1166323.	4.6	36
103	Intermittent PI3KÎ´ inhibition sustains anti-tumour immunity and curbs irAEs. Nature, 2022, 605, 741-746.	27.8	36
104	Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. British Journal of Cancer, 2015, 113, 107-118.	6.4	34
105	Synthesis and inâ€¦vitro Evaluation of Î±â€‘GalCer Epimers. ChemMedChem, 2008, 3, 1061-1070.	3.2	33
106	The immune response in HPV$^+$ oropharyngeal cancer. OncoImmunology, 2014, 3, e27254.	4.6	32
107	COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types. Nature Communications, 2021, 12, 6760.	12.8	32
108	Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?. Leukemia, 2006, 20, 530-534.	7.2	31

#	Article	IF	Citations
109	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. OncoImmunology, 2018, 7, e1433516.	4.6	31
110	CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage. , 2020, 8, e000473.		31
111	Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 ⁺ T Cells. SSRN Electronic Journal, 2020, , 3641939.	0.4	31
112	Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Research, 2020, 80, CT301-CT301.	0.9	31
113	Synthesis and In Vivo Evaluation of 4-Deoxy-4,4-difluoro-KRN7000. Organic Letters, 2008, 10, 4433-4436.	4.6	30
114	Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunology, Immunotherapy, 2014, 63, 1199-1211.	4.2	30
115	Serum is not required for ex vivo IFN-Î³ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunology, Immunotherapy, 2010, 59, 619-627.	4.2	29
116	CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. Journal of Thoracic Oncology, 2018, 13, e193-e196.	1.1	29
117	CD8⁺ Tâ€cell crossâ€competition is governed by peptideâ€"MHC class I stability. European Journal of Immunology, 2012, 42, 256-263.	2.9	28
118	Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. Cancer Immunology, Immunotherapy, 2018, 67, 627-638.	4.2	28
119	Importance of the immune system in head and neck cancer. Head and Neck, 2019, 41, 2789-2800.	2.0	28
120	Anti-idiotype vaccines. British Journal of Haematology, 2003, 123, 770-781.	2.5	27
121	Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunology, Immunotherapy, 2013, 62, 615-627.	4.2	27
122	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunology, Immunotherapy, 2015, 64, 1021-1032.	4.2	27
123	Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. OncoImmunology, 2018, 7, e1395125.	4.6	26
124	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. Clinical Cancer Research, 2016, 22, 4827-4836.	7.0	24
125	COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European Journal of Cancer, 2017, 87, 75-83.	2.8	24
126	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncology, 2018, 14, 2415-2431.	2.4	24

#	ARTICLE	IF	CITATIONS
127	HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC. Cancer Immunology Research, 2019, 7, 1202-1213.	3.4	24
128	Vaccination Expands Antigen-Specific CD4+ Memory T Cells and Mobilizes Bystander Central Memory T Cells. PLoS ONE, 2015, 10, e0136717.	2.5	23
129	Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. Cell Death Discovery, 2020, 6, 54.	4.7	23
130	Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. Clinical Cancer Research, 2017, 23, 7641-7649.	7.0	22
131	FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. Journal of Clinical Oncology, 2022, 40, 9510-9510.	1.6	22
132	The Synthesis and inâ€¦vivo Evaluation of 2â€²,2â€²â€Difluoro KRN7000. ChemMedChem, 2009, 4, 329-334.	3.2	21
133	DNA fusion vaccines enter the clinic. Cancer Immunology, Immunotherapy, 2011, 60, 1147-1151.	4.2	21
134	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
135	First case report of Muirâ€"Torre syndrome associated with non-small cell lung cancer. Familial Cancer, 2009, 8, 359-362.	1.9	20
136	Absence of constitutive EGF receptor activation in ovarian cancer cell lines. British Journal of Cancer, 1996, 74, 446-452.	6.4	18
137	Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunology, Immunotherapy, 2015, 64, 585-598.	4.2	18
138	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2000-2000.	1.6	17
139	Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunology, Immunotherapy, 2009, 58, 789-800.	4.2	16
140	The adaptive immune response to colorectal cancer: From the laboratory to clinical practice. European Journal of Surgical Oncology, 2012, 38, 889-896.	1.0	16
141	The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunology, Immunotherapy, 2013, 62, 489-501.	4.2	16
142	DNA fusion gene vaccines induce cytotoxic Tâ€cell attack on naturally processed peptides of human prostateâ€specific membrane antigen. European Journal of Immunology, 2011, 41, 2447-2456.	2.9	15
143	BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY. Retinal Cases and Brief Reports, 2018, 12, 184-187.	0.6	15
144	Taking Electroporation-Based Delivery of DNA Vaccination into Humans: A Generic Clinical Protocol. Methods in Molecular Biology, 2008, 423, 497-507.	0.9	15

#	ARTICLE	IF	CITATIONS
145	TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy, 2016, 8, 511-519.	2.0	14
146	Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. OncoImmunology, 2016, 5, e1209615.	4.6	14
147	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. International Immunopharmacology, 2022, 110, 108985.	3.8	14
148	The classification of lymphomas and leukemias. Chemico-Biological Interactions, 2001, 135-136, 653-664.	4.0	13
149	Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients. British Journal of Cancer, 1999, 81, 1213-1221.	6.4	12
150	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. Blood, 2000, 96, 2550-2556.	1.4	12
151	Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European Journal of Cancer, 2014, 50, 1717-1721.	2.8	12
152	Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA–Peptide Multimer Staining Assay. Cytometry Part B - Clinical Cytometry, 2018, 94, 342-353.	1.5	12
153	Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. Annals of Oncology, 2018, 29, viii497.	1.2	12
154	The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. BMJ Open, 2019, 9, e031531.	1.9	12
155	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 2021, 21, 761.	2.6	12
156	Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. , 2022, 10, e003821.		12
157	DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. Frontiers in Immunology, 2021, 12, 763086.	4.8	9
158	HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 131.	8.6	9
159	Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Research, 2022, 32, 103-111.	1.2	8
160	Suppression of Hedgehog signalling promotes pro–tumourigenic integrin expression and function. Journal of Pathology, 2014, 233, 196-208.	4.5	7
161	Early-Phase Interventional Trials in Oral Cancer Prevention. Cancers, 2021, 13, 3845.	3.7	7
162	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. Cancers, 2021, 13, 4875.	3.7	7

#	ARTICLE	IF	CITATIONS
163	Wilms' tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). Efficacy and Mechanism Evaluation, 2016, 3, 1-80.	0.7	7
164	Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. European Journal of Cancer, 2022, 166, 287-299.	2.8	7
165	CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer. Frontiers in Immunology, 2022, 13, 842653.	4.8	7
166	Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. Current Topics in Microbiology and Immunology, 2016, 405, 123-143.	1.1	6
167	Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). International Journal of Cancer, 2021, 148, 2023-2035.	5.1	6
168	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. Blood, 1998, 91, 4292-4299.	1.4	6
169	Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. BMJ Open, 2022, 12, e041961.	1.9	6
170	A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer. Chemotherapy, 2012, 58, 257-263.	1.6	5
171	CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. Cancers, 2020, 12, 2963.	3.7	5
172	Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment. Neuroendocrinology, 2022, 112, 370-383.	2.5	5
173	CD8 T‑cell‑mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	5
174	Abstract 3762: Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. , 2019, , .		5
175	Cancer Vaccines. , 2007, , 183-204.		4
176	The role of the reporting framework MIATA within current efforts to advance immune monitoring. Journal of Immunological Methods, 2014, 409, 6-8.	1.4	4
177	Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. PLoS ONE, 2016, 11, e0155059.	2.5	4
178	C1-03: A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, S359.	1.1	4
179	Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.. Journal of Clinical Oncology, 2015, 33, e20000-e20000.	1.6	4
180	A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2018, 36, 6068-6068.	1.6	4

#	ARTICLE	IF	CITATIONS
181	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. Blood, 2000, 96, 2550-2556.	1.4	4
182	Histological transformation of indolent (follicular) lymphoma. Annals of Oncology, 1996, 7, 849-853.	1.2	3
183	Survival from melanoma of the skin in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S50-S52.	6.4	3
184	Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC. Frontiers in Oncology, 2020, 10, 591063.	2.8	3
185	Vaccine Therapy in NHL: Future Promises and Current Limitations. Leukemia and Lymphoma, 2003, 44, S85-S90.	1.3	2
186	Novel players: tissue-resident memory B cells. Blood, 2020, 136, 2722-2723.	1.4	2
187	An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).. Journal of Clinical Oncology, 2021, 39, TPS9138-TPS9138.	1.6	2
188	Phase I trial of ImmunoBody in melanoma patients.. Journal of Clinical Oncology, 2014, 32, 3061-3061.	1.6	2
189	Abstract 5084: Characterizing heterogeneity in the cancer-associated fibroblast population in non-small cell lung cancer: Relating phenotype to function. , 2018, , .		2
190	Idiotype Gene Rescue in Follicular Lymphoma. , 2005, 115, 145-172.		1
191	Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines. Clinical Lymphoma and Myeloma, 2009, 9, S23-S24.	1.4	1
192	Genetic Vaccines against Cancer. , 2013, , 223-239.		1
193	Novel Approaches for Vaccination Against HPV-Induced Cancers. Current Topics in Microbiology and Immunology, 2015, 405, 33-53.	1.1	1
194	Towards personalised medicine in lung and thymus neuroendocrine tumours. Lancet Oncology, The, 2017, 18, 1563-1565.	10.7	1
195	Melanoma-reactive T cells take up residence. Nature Cancer, 2021, 2, 253-255.	13.2	1
196	Abstract LB-142: A trial of agonistic anti-CD40 antibody: Biological effects in a Cancer Research UK phase I study.. , 2013, , .		1
197	Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. , 2014, , .		1
198	Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. , 2016, , .		1

#	ARTICLE	IF	CITATIONS
199	An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells <i>in vivo</i>, in fully resected melanoma patients.. Journal of Clinical Oncology, 2015, 33, 9035-9035.	1.6	1
200	T _{FR} Cells Inhibit Anti-Tumor Immunity and are Responsive to Immune Checkpoint Blockade. SSRN Electronic Journal, 0, , .	0.4	1
201	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2012, 30, TPS8605-TPS8605.	1.6	1
202	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2015, , 471-490.		1
203	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2020, , 761-783.		1
204	Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response. Frontiers in Oncology, 2022, 12, 862694.	2.8	1
205	Abstract CT213: A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY). Cancer Research, 2022, 82, CT213-CT213.	0.9	1
206	Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA). Cancer Research, 2022, 82, CT214-CT214.	0.9	1
207	NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.. Journal of Clinical Oncology, 2022, 40, TPS2682-TPS2682.	1.6	1
208	Dose Seeking Evaluation of a Novel Heterologous Primeboost Immunotherapy in Stage III and IV Metastatic Melanoma Patients. Journal of Immunotherapy, 2004, 27, S27.	2.4	0
209	119 Phase I dose finding study of irinotecan in combination with carboplatin in treatment naive extensive stage small cell lung cancer. Lung Cancer, 2011, 71, S41.	2.0	0
210	T-cell immune monitoring assays to guide the development of new cancer vaccines. , 2011, , 156-166.		0
211	New horizons for prostate cancer: part 2. Trends in Urology & Men's Health, 2013, 4, 13-16.	0.4	0
212	New horizons for prostate cancer: part 1. Trends in Urology & Men's Health, 2013, 4, 38-40.	0.4	0
213	PUB035 CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S2376.	1.1	0
214	Real-world use of anti-PD-1 checkpoint inhibitors in the management of non-small cell lung cancer: experience from a large UK teaching hospital. Lung Cancer, 2018, 115, S35.	2.0	0
215	Immunotherapy in the immunodeficient: A treatment paradox?. Annals of Oncology, 2018, 29, viii429.	1.2	0
216	CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. Lung Cancer, 2018, 115, S84.	2.0	0

#	Article	IF	Citations
217	ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi5-vi5.	1.2	0
218	LSC Abstract â€" Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. , 2016, , .		0
219	LSC Abstract â€" Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. , 2016, , .		0
220	Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).. Journal of Clinical Oncology, 2017, 35, TPS9099-TPS9099.	1.6	0
221	Abstract 2948: A distinct CD8+tumor infiltrating lymphocyte subset is associated with high TIL density, enhanced cytotoxicity and improved survival in patients with lung cancer. , 2017, , .		0
222	Transcriptomic profiling reveals M1-high tumour associated macrophages that orchestrate the adaptive Anti-tumour response in human lung cancer. , 2017, , .		0
223	Immunotherapy in metastatic melanoma: When is it safe to stop?. Journal of Clinical Oncology, 2018, 36, e21518-e21518.	1.6	0
224	CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.. Journal of Clinical Oncology, 2018, 36, TPS8586-TPS8586.	1.6	0
225	Abstract LB-143: Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients. , 2018, , .		0
226	Exosomal microRNAs in the lung: eliciting long-term intercellular communication?. , 2018, , .		0
227	An Optimized Method to Isolate Human Fibroblasts from Tissue for Ex Vivo Analysis. Bio-protocol, 2019, 9, e3440.	0.4	0
228	Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. , 2019, , .		0
229	Abstract B139: Plant viral particle vaccine induces a potent antitumor response through induction of antigen-specific T-cells and overcoming an immunosuppressive tumor microenvironment. , 2019, , .		0
230	Abstract 3762: Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. , 2019, , .		0
231	Abstract 1466: Combination immunotherapy successfully control tumor growth in a transgenic mouse model. , 2019, , .		0
232	Abstract PO-039: Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer. , 2020, , .		0
233	Tissue resident memory T cells (TRM) in primary, metastatic and recurrent head and neck squamous cell carcinoma (HNSCC) tissue. Laryngo- Rhino- Otologie, 2022, , .	0.2	0
234	GewebsansÄssige GedÄchtnis-T-Zellen (TRM) in primÄrem, metastasiertem und rezidivierendem Plattenepithelkarzinom des Kopfes und Halses (HNSCC). Laryngo- Rhino- Otologie, 2022, , .	0.2	0